Tergenpumatucel-L

Drug Profile

Tergenpumatucel-L

Alternative Names: HyperAcute Lung; HyperAcute Lung immunotherapy; Lung cancer vaccine - NewLink Genetics; Turgenpumatucel-L

Latest Information Update: 07 Nov 2015

Price : $50

At a glance

  • Originator NewLink Genetics Corporation
  • Class Cancer vaccines; Cell therapies; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Non-small cell lung cancer

Most Recent Events

  • 03 Nov 2015 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intradermal) (NCT02460367)
  • 05 Jun 2015 NewLink Genetics Corporations plans a phase II trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (NCT02460367)
  • 27 May 2015 Phase IIb/III development is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top